Legend Biotech (LEGN) Asset Writedowns and Impairment (2020 - 2025)

Legend Biotech has reported Asset Writedowns and Impairment for 5 years, with the latest figure at $865000.0 in Q3 2025.

• For the quarter ending Q3 2025, Asset Writedowns and Impairment rose 114.64% year-over-year to $865000.0; the trailing twelve-month figure through Sep 2025 stood at -$3.6 million (down 147.37% YoY), and the FY2020 full-year result was $280.2 million, changed N/A from the prior year.
• Asset Writedowns and Impairment for Q3 2025 stood at $865000.0, up from -$1.1 million in the prior quarter.
• The five-year high for Asset Writedowns and Impairment was $339.9 million in Q2 2021, with the low at -$3.8 million in Q1 2025.
• Historically, Asset Writedowns and Impairment has averaged $51.8 million across 4 years, with a median of $767000.0 in 2023.
• Annual changes were most pronounced in 2024 — Asset Writedowns and Impairment soared 1965.49% — and 2025, when it sank 316.16%.
• Legend Biotech's Asset Writedowns and Impairment stood at $225.8 million in 2021, then slumped by 99.66% to $767000.0 in 2023, then plunged by 47.46% to $403000.0 in 2024, then jumped by 114.64% to $865000.0 in 2025.
• The last three Asset Writedowns and Impairment figures came in at $865000.0 (Q3 2025), -$1.1 million (Q2 2025), and -$3.8 million (Q1 2025), per Business Quant data.